GLP-1 RAs for type 2 diabetes significantly lower one-year mortality, especially in those also diagnosed with obstructive sleep apnea.

The FDA will complete the approval process for certain medications in 1 to 2 months, a change from the usual 10-month review.

Low-carbohydrate diets, especially ones focused on animal-based protein and fat, were overall associated with an increased risk for type 2 diabetes.

Smoking cessation increased overall survival in cancer survivors who smoked, regardless of disease stage, compared with current smoking.

A diagnosis of distant breast, colorectal, or non-small cell cancer was less likely among individuals receiving housing assistance than among matched control individuals, compared to a localized ...

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

Obeticholic acid added to ursodeoxycholic acid improved alkaline phosphatase and bilirubin levels among patients with PBC unresponsive to first-line therapy.

California will start selling a generic version of glargine at a recommended price of $11 per pen, or $55 for a five-pack, January 1.

Prior authorizations affect 74% of people with cancer, of whom half reported that the health care teams fully handled it.

New code E11.A applies to patients who use lifestyle interventions to show no signs of type 2 diabetes for at least 3 months.

Nearly 700 medicines used in the US to treat common conditions contain at least 1 chemical sourced only in China.

Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.